AVANIR Pharmaceuticals (AVNR) Announces Appointment of Corinne Nevinny to Board of Directors

ALISO VIEJO, Calif., March 11, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Ms. Corinne Nevinny to the company's board of directors. Ms. Nevinny, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience across multiple disciplines.

Ms. Nevinny is General Partner of LMNVC LLC, a privately held early stage venture firm, which she founded in October 2010. Prior to that position, Ms. Nevinny served as corporate vice president for seven years at Edwards Lifesciences Corporation, a leading cardiovascular technology company. She held several positions at the company including general manager of Cardiac Surgery Systems and Vascular, president of Global Operations, and chief financial officer and treasurer. Other positions Ms. Nevinny held included vice president and chief financial officer of Tularik, Inc, a biotechnology company acquired by Amgen and executive director in the health care group at Warburg Dillon Read LLC, an investment bank.

Ms. Nevinny also serves on the board of directors of Onyx Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., as well as three private companies. Ms. Nevinny received her undergraduate degree from Stanford University and her M.B.A. from Harvard Business School.

"It is a pleasure to welcome Corinne to the Avanir Board," commented chairman of the board, Craig Wheeler. "Her knowledge and expertise in finance, operations, and the life sciences industry will complement the strengths and talents of our existing board members."

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
[email protected]
+1 (949) 389-6700

SOURCE Avanir Pharmaceuticals, Inc.

Suggested Articles

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.

The new parliamentary arithmetic gives Boris Johnson the numbers to pass the withdrawal agreement and take the U.K. out of the EU.

The discovery that 500 cancers can be slotted into 10 subtypes, each of which is driven by a common set of proteins, could inspire new therapies.